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Summary In this study the localisation of porphyrinoid photosensitisers in tumours was investigated. To
determine if tumour selectivity results from a preferential uptake or prolonged retention of photosensitisers,
intravital fluorescence microscopy and chemical extraction were used. Amelanotic melanoma (A-Mel-3) were
implanted in a skin fold chamber in Syrian Golden hamsters. Distribution of the porphyrin mixture Photofrin
and three porphycenes, pure porphyrinoid model compounds, was studied quantitatively by intravital
fluorescence microscopy. Extraction of tissue and blood samples was performed to verify and supplement
intravital microscopic results. Photofrin accumulated in melanomas reaching a maximum tumour:skin tissue
ratio of 1.7:1. Localisation of the different porphycenes was found to be highly tumour selective (3.2:1),
anti-tumour selective (0.2:1), and non-selective (1:1) with increasing polarity of the porphycenes. The two
non-tumour selective porphycenes had distinctly accelerated serum and tissue kinetics; serum halflife times
being as short as 1 min. The specific localisation of the slowly distributed, tumour selective photosensitisers,
occurred exclusively during the distribution from serum and uptake into tissues. For the most selective
porphycene, the tumour selection process had a halflife of 260 ± 150 min and led to a strongly fluorescent
tumour edge edema. Accumulation of porphyrines by the amelanotic melanoma (A-Mel-3) can be attributed
to an enhanced uptake rate for lipophilic molecules in this subcutaneously growing neoplasm. The slow
distribution of the two tumour specific photosensitisers and the strong fluorescence of these hydrophobic
molecules in the tumour compartment with a high water content indicate a carrier role of serum proteins in
the selection process. Enhanced permeability of the tumour vasculature to macromolecules appears to be the
most probable reason for the tumour selectivity of these two sensitisers.
In the first half of this century it was shown that systemically
administered porphyrines preferentially localise in neoplasms
of tumour-bearing animals (Policard, 1924; Auler et al.,
1942). This phenomenon found diagnostic application as a
method for tumour detection utilising the red fluorescence of
the porphyrines (Lipson et al., 1961a,b; Baumgartner et al.,
1987). The photosensitising properties of these molecules
(Meyer-Betz, 1913) were exploited for therapeutic purposes
and allowed the establishment of photodynamic therapy
(PDT) as a new treatment modality for tumours (Dougherty
et al., 1978).
The mechanisms leading to the tumour specific localisation
of the porphyrines are still under investigation (Moan et al.,
1992). Experimental progress has been complicated by the
fact that even the most purified photosensitiser, Photofrin
(Pf), is a complex mixture of molecular species with very
similar spectral characteristics (Dougherty, 1987; Pandey et
al., 1990).
In the present investigation, the localisation of three
chemically pure synthetic porphyrinoids in an amelanotic
melanoma grown in a transparent hamster skin chamber
(Endrich et al., 1980) was studied fluorometrically and com-
pared with the localisation of Photofrin. This tumour model
has been used before for the study of microcirculation in
neoplastic tissue (Asaishi et al., 1981; Endrich et al., 1982).
Porphycenes (Vogel et al., 1986) were selected as pure por-
phyrin model compounds for their high absorption and
fluorescence yields (Aramendia et al., 1986; Kreimer-
Birnbaum, 1989) and their well-established chemistry (Vogel,
1990). The three porphycenes employed varied in the number
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of polar substitutents and thus in lipophilicity. The ether,
ester, hydroxy and carboxy groups present in these por-
phycenes are those functionalities found in the analysis of
Photofrin (Pandey et al., 1990). Two of the porphycenes
employed (the trietherporphycenes HEPn and CBPn) have
already been shown to eradicate amelanotic melanomas of
hamsters when irradiated at a dose level where photofrin had
no phototherapeutic effect (Dellian et al., 1992).
The aim of our study was to distinguish between uptake
and retention type mechanisms in the tumour localisation
process by measuring the time dependence of drug content in
blood, skin tissue, and a melanoma in the hamster.
Methods
Photosensitisers
9-Acetoxy-2,7,12,17-tetrapropylporphycene (ATPPn) was
prepared from tetrapropylporphycene (Vogel et al., 1987),
2-hydroxyethyl-7,12,17-tris(methoxyethyl)porphycene (HEPn)
and 23-carboxy-24-methoxycarbonylbenzo[2,3]-7,12,17-tris
(methoxyethyl)-porphycene (CBPn) were prepared from tetra-
kis(methoxyethy)porphycene (Vogel et al., manuscript in
preparation). Structural formulae of the porphycenes em-
ployed in this study are shown in Figure 1. Porphycenes were
characterised by NMR, mass-, IR- and UV-Vis spectroscopy
and had a purity >97% as monitored by HPLC. The polarity
of the porphycenes employed rises in the order
ATPPn<HEPn <CBPn as demonstrated by the polarity of
solvents necessary to elute each molecule from silica gel
columns (0.063-0.2 mm, E. Merck, Darmstadt, Germany)
that were run at ambient pressure with 20 g silica for each
1Omg porphycene sample. Additives (1:1 vv) to dichloro-
'A further finding supporting this hypothesis is that the water con-
tent in A-Mel-3 tumours (200-300 mm3) is about 81%, whereas the
water content of skin tissue in hamsters is only 54% (Leunig, M.,
unpublished data).
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methane were hexane for ATPPn, ethylacetate for HEPn and
methanol for CBPn for comparable retention times. The
polarity of these additives as defined by the polarity index P'
of Snyder (1974) is 0.0 for hexane, 4.3 for ethylacetate and
6.6 for methanol.
Photofrin (Lederle, Wolfrathshausen, Germany) and L-a-
dioleylphosphatidylcholine, purity >99%, and 9,10-
diphenylanthracene, purity >99% (Sigma, Deisenhofen,
Germany) were used without modifications. Organic solvents
were at least analytical grade and PBS was Dulbecco's with-
out Ca2+ and Mg2+.
Liposomes
Porphycenes were incorporated in small unilamellar vesicles
of dioleylphosphatidylcholine (DOPC; diameter: 110 +
30 nm) on a molar ratio 1:200 to allow a quantitative follow-
up and to avoid deviations in fluorescence intensity by aggre-
gation as detailed elsewhere (Richert, in press). Shortly, a
film produced by coevaporation of phosphatidylcholine and
porphycene solutions in chloroform/methanol (9:1, both
purisss., Merck, Darmstadt, Germany) was taken up in PBS
to yield a 0.1 M lipid suspension. Samples (1.8 ml) were
sonicated with a Branson probe sonicator and subjected to
0.2Itm sterile filtration after 24 h annealing time. Accuracy of
preparation was monitored by UV/Vis spectroscopy of diluted
aliquots. All steps were carried out under argon protective
gas and samples were stored at room temperature in the
dark. DOPC small unilamellar vesicles incorporate the por-
phycenes employed in monomeric, photoactive form, as
monitored by time resolved fluorescence spectroscopy.
Liposomal porphycene formulations were tested for their
ability to release the sensitisers in vivo. To this end, after
injection porphycenes were extracted from erythrocytes by
the same procedure as described for serum.
Animals and tumour model
Experiments were performed on 23 male Syrian Golden
hamsters (60-70 g b.w.) fitted with titanium chambers (for
technical details see Endrich et al., 1980). Following implan-
tation of the transparent access chamber and a recovery
period of 48 h from anaesthesia and microsurgery, prepara-
tions fulfilling the criteria of an intact microcirculation were
utilised for implantation of 2 x 105 cells of the amelanotic
hamster melanoma A-Mel-3 into the chamber preparation.
Fluorescence microscopy was performed after 6-7 days of
growth (mean tumour diameter of 4-5 mm) when function-
ing tumour microcirculation was established. Permanently
indwelling catheters (PE10, inner diameter 0.28 mm) were
implanted into the right jugular vein and/or carotid artery
24 h prior to photosensitiser injection. The animals tolerated
the catheters and chambers well and showed no signs of
discomfort.
After i.v. photosensitiser injection, animals were housed in
absolute darkness in single cages under carefully controlled
temperature conditions with free access to water and stan-
dard pellet food.
In vivofluorescence measurements
For fluorescence microscopy the awake, chamber bearing
hamsters, laying in the perspex tube on a specially designed
stage (Effenberger, Munich, Germany), were positioned
under a modified Leitz microscope (Type 307-143003/514660,
Leitz, Munich, Germany) and monitored with a 14-fold
magnification (Figure 2). During the experiments, the animal
temperature was kept constant using a feed back controlled
heating pad (Effenberger, Munich, Germany). Epi-
illumination was performed with a 100 W, XBO mercury
lamp attached to a Ploemopak illuminator.
For visualisation of the photosensitiser fluorescence, the
tissue was illuminated 2 s at a power density of
200-300ytw cm-2. Porphycene fluorescence was excited at a
wavelength of 340-380 nm, Pf fluorescence at 355-425 nm.
The emission fluorescence of the porphycenes and Pf was
detected above 610 nm. Fluorescence images were recorded
by means of a silicon intensified target (SIT) (100-0.lmLux)
video camera (C2400-08, Hamamatsu, Herrsching, Ger-
many). Digitisation was performed using an image analysis
system (IBAS 2000, Kontron, Eching, Germany) and images
were later stored on a hard disc.
This procedure was performed prior to photosensitiser
application to record the tissue auto-fluorescence and
repeated at defined time points (30 s, 1, 3, 5, 15, 30 min, 1, 3,
6, 24, 48, and 72 h) after i.v. injection of 1.4ytmol kg-' b.w.
of either porphycenes (ATPPn n = 7, HEPn n = 6, CBPn
n = 4) or 5 mg kg-' b.w. Photofrin (n = 6). The photosen-
sitiser doses were based on pilot studies, where
concentration-fluorescence linearity was determined and are
in the therapeutical range for the porphycenes and Photofrin
(Dellian et al., 1992).
Photosensitiser fluorescence intensities were measured den-
sitometrically off-line by means of the image analysis system
(IBAS, Kontron, Eching, Germany) and tissue auto-
fluorescence was digitally subtracted. Changes of the camera
sensitivity or the light intensity during the experiments were
corrected using solid fluorescent reference signals (Impregum
F, Seefeld, Germany) inserted into the observation field of
the chamber preparation. Photostability of solid references
was proved using a 5 nmol ml1' tetrapropylporphycene
toluene solution, known to be photostable (Aramendia et al.,
Nr)t :N OCOCH3
H H
N N
ATPPn
HO OCH3
N N\
H H
.N N/
H3CO OCH3
HEPn
CO2H
p CO2CH3 OCH3
,N N
H H
\N NH
H3CO OCH3
CBPn
Increase in polarity
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Skin fold chamber \
Perspex stage
Figure 2 For fluorescence microscopy, awake hamsters were immobilised in a perspex tube and the skin fold preparation
containing the melanoma was attached to the perspex stage. The stage was positioned under a microscope and skin and tumour
tissue in the dorsal chamber preparation were illuminated by the excitation light. Resulting fluorescence images detected by a SIT
camera were directly digitised (image processing system) and stored on a hard disc. In addition, images were recorded on tapes of a
video cassette recorder. Image analysis was performed off line using the image processing system.
1986). All fluorescence values are given in percent of the
reference fluorescence signal (% Ref.). The geometric resolu-
tion of the digitised images was 512 x 512 pixel by a den-
sitometric resolution of 255 grey values. Photosensitiser
fluorescence in tumour and adjacent tumour-free tissue was
determined in defined areas (250fLm2) by digital light
measurement. These defined areas did not overlay blood
vessels with a diameter >30 im. The image analysis was
used for an interactive frame positioning. Thus areas of
measurement were identical for all time points. Spatial
inhomogeneities of the light source and the camera were
compensated by shading correction performed with the image
analysis system.
Chemical extraction
After the final intravital microscopic measurement, animals
were sacrificed by an overdose of anaesthesia (Pentobarbital,
500 mgkg-' b.w.) i.p. and tissue specimens of the tumour
and adjacent tumour-free tissue were immediately excised
and frozen in liquid nitrogen for chemical extraction.
To enable measurement of rapid serum kinetics for the
three porphycenes (dose: 1.4timol kg-' b.w.), a two catheter
blood sampling technique was applied to a second group of
21 hamsters (ATPPn n = 8, HEPn n = 9, CBPn n = 4). The
minimum interval between injection and sampling was 30 s.
Blood samples (401g) from anesthetised hamsters bearing a
venous catheter as described above and an additional
catheter implanted in the right carotid artery were taken in
heparinised capillaries. The samples were centrifuged to
determine the hematocrit and to isolate serum used for
chemical extraction.
Serum and tissue specimens were extracted by a procedure
that recovered 85 ± 5% of every porphycene employed from
serum and erythrocytes, and extracted <10% of the initially
extracted amount of dye from the tissue sediments in re-
extraction experiments. Tenftl serum samples or weighed
amounts of tumour and tumour-free tissue (5-20 mg), cut in
small pieces, were treated with methanol. Serum probes were
briefly agitated and tissue specimen homogenised in a Potter-
Elvehjem vessel followed by subsequent additions of acetoni-
trile containing Diphenylanthracene (DPA) reference
standard. Samples were sonicated, and centrifugation yielded
a supernatant that was subjected to spectrofluorometric
analysis. The efficiency of the extraction procedure was deter-
mined by comparing the fluorescence of extracts from por-
phycenes incubated either with erythrocytes, serum or buffer
alone (control).
Emission spectra were recorded on a spectrofluorometer
equipped with a red sensitive phototube at a 5 nm slidewidth.
Light source intensity was calibrated against 10-7M tet-
raphenylbutadiene solid standard in a polymethylmethacry-
late matrix (Starna, Pfungstadt, Germany). Peak intensities
were read against DPA internal standard intensities at
429 nm and compared to the porphycene calibration plots.
ATPPn 72 h tissue extracts eventually exhibited an additional
670 ± 10 nm peak, showing porphycene excitation charac-
teristics, whose intensity was quantified as the ATPPn
644 nm maximum.
During the sampling, some of the interstitial fluid was lost
(<20%), which might have led to a slightly lower tumour
selectivity of ATPPn (Table IV) compared to the microscopic
measurements.
The extraction protocol was restricted to the porphycenes
since no method for the quantitative extraction of Photofrin,
whose chemical composition is still partly unknown (Pandey
et al., 1990) could be established.
Mathematical analysis andstatistics
Least square fits, using a Marquardt algorithm (Bevington,
1969), were employed for the serum kinetics. Serum kinetics
were analysed according to the two compartment model
(Benet et al., 1980). Eventual deviations of injected sensitiser
dose were corrected, by factorising deviation from 1 min
averages of individual serum concentrations. Loss of blood
volume caused by repeated blood sampling from the animals
was corrected for by adjusting serum concentrations to the
actual hematocrit.
For nonparametric one-way analysis of variance and mul-
tiple comparison of ranks of several independent samples, the
Kruskal-Wallis test was utilised. Single comparisons of
unpaired samples were performed using U-test and of paired
samples by the Wilcoxon-test. Data are given as mean ± stan-
dard deviation (SD) or standard error of the mean (SEM),
respectively. Tumour:skin tissue fluorescence ratios (Figure
6) are means of ratios of individual animals, diverging
slightly from the ratio of mean fluorescence of each tissue
(Figure 5).228 M. LEUNIG et al.
Results
Pharmacokinetics of the porphycenes showed a strong
dependence on the chemical properties of the sensitisers
(Figure 1 and Figure 4). For each single porphyrinoid, time
constants for uptake and elimination from melanomas were
similar to those found for skin tissue and blood. The rates of
accumulated or eliminated molecules, however, differed dis-
tinctly between the tissues monitored.
Halflife of distribution from serum decreased in the order
ATPPn> HEPn = CBPn (Figure 3, and Table I). HEPn
additionally exhibited a redistribution phase in its serum
kinetics prolonging its full distribution and reflecting the
HEPn>CBPn order in tissue uptake. Actual serum halflives
of distribution were determined to be 7 h for the alkylpor-
phycene ATPPn and 1 min for both etherporphycenes by the
fit procedure (Table I). The redistribution process had a
halflife of 1 h for HEPn (Table I). Elimination halflife also
decreased in the order ATPPn>HEPn>CBPn, with values
50
40
E
a) E
CD)
10
30 T
-
-6
E
-5
a)
0
C,)
of more than 1 day for ATPPn, about half a day for HEPn,
and 3 h for CBPn. Thus, the acceleration of the phar-
macokinetics followed the polarity of the porphycenes.
One minute after injection, the most lipophilic alkylpor-
phycene ATPPn had not penetrated erythrocytes effectively,
whereas both trietherporphycenes were found in considerable
amounts in red blood cells. At that time, dye concentration
ratio of serum to red blood cells was 130:1 for ATPPn, 2.3:1
for HEPn, and 1.4:1 for CBPn (Table II). After 10h, less
than 10% of the serum concentration of ATPPn was found
in erythrocytes.
Tissue uptake, defined as the time interval to reach maxi-
mum tissue fluorescence, was shortened in the order
CBPn>HEPn>Pf>ATPPn. Maximum fluorescence inten-
sity in tumours was detected 30 s after injection for CBPn,
3 h after injection of HEPn, and 24 h after injection of
ATPPn (Figure 4). Tumour fluorescence reached a maximum
6 h after Pf injection and increased again after 24 h, though
not significantly.
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Figure 3 Serum-kinetics of porphycenes. a, ATPPn; b, HEPn; c, CBPn. Serum-levels were spectrofluorometrically measured from
extracted samples. Bars indicate typical errors, taken from the s.d. of repeated extraction of one sample in every concentration
range. Lines give results of fit procedure. The insert is a bilogarythmic plot of identical values. Note the x-axis of the CBPn plot
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Table I Serum distribution (D), redistribution (R), and elimination
(E) halflives of the porphycenes
Porphycene tjD (min) tjR (min) tjE (min)
ATPPn 430± 30 - 1700 ± 1300
HEPn 0.91 ± 0.1 62 ± 8 500 ± 160
CBPn 1.1±0.3 - 170±30
Values are derived from fits to serum-kinetics, determined by
chemical extractions; errors are s.d.
Table II Porphycene concentration ratios serum to erythrocytes
1 min after i.v. injection
Sensitiser RatiocserumIcervs
ATPPn 130:1
HEPn 2.3:1
CBPn 1.4:1
Fluorometric measurements in the tumour bearing
chambers demonstrated that uptake and elimination in the
skin tissue was coincident with uptake and elimination in the
melanoma for all sensitiser tested, however, the amount of
photosensitisers detected in both tissues differed distinctly.
Both fluorescence and extraction measurements yielded this
result independently (Figure 4, Table III and IV). Only two
of the photosensitisers (ATPPn and Pf) were found to
localise preferentially in tumours. ATPPn was delivered far
more effectively to tumours than to non-neoplastic tissue.
Photofrin also accumulated in the melanoma, though in a
less pronounced way. HEPn only showed slight tumour selec-
tivity 30 s after injection, but later reached higher concentra-
tions in subcutaneous host tissue than in tumours. To our
knowledge, HEPn is the first photosensitiser that localises
'anti-tumour-selectively'. The most polar porphycene, CBPn,
showed no specificity for the fluorometrically monitored tis-
sues.
The time courses in tumour specificity are given as the
fluorescence ratio of tumour:skin tissue in Figure 5. These
'selectivity functions' showed a strong time dependence for
ATPPn and HEPn and to a lesser degree for Photofrin. The
maximum tumour selectivity ratio was 3.2 for ATPPn, 1.7
for Pf, and 1.3 for HEPn (Table IV). Increases in tumour
selectivity occurred during the uptake phases of tissue
kinetics for the tumour-selective sensitisers ATPPn, Pf, and
HEPn. The halflife for the tumour selection process of
ATPPn equalled the serum distribution constant within ex-
perimental error. The time constant for selectivity of HEPn
was between the halflives for redistribution and elimination
from the serum. No increase in tumour selectivity was seen
during elimination periods from tissues and serum for any of
the sensitisers tested and decreased for both the highly tissue
specific porphycenes ATPPn and HEPn.
Fluorescence pictures taken of tumour chambers 24 h after
dye injection (Figure 6) showed peak emission intensities at
tumour edges for ATPPn. The anti-tumour selective por-
phycene, HEPn, was located in large, diffuse spots and
stripes in the subcutaneous tissue and was not localised in
tumours and/or the vasculature as evidenced by fluorometric
measurements.
Discussion
The elucidation of the tumour localisation of porphyrin(oid)s
presents a challenge to PDT researchers, since understanding
of the underlying mechanism(s) might allow the design of not
only improved photodynamic, but also non-photodynamic
drugs. Intravital microscopy of tumours grown in skin
chambers has proved to be a valuable tool for the study of
microcirculation (Endrich et al., 1989; Asaishi et al., 1981;
Leunig et al., 1992). It appears to be a suitable technique for
the study of porphyrinoid localisation since these PDT drugs
can be directly visualised by their fluorescence. Thus phar-
macokinetics can be determined at the microscopic level
without artifacts caused by sacrifice of the animal with high
experimental accuracy, since the local pharmacokinetic can
be measured from one individual. Additionally fast
diffusional processes, not observable by ex vivo techniques,
can be monitored. However, care must be taken to ensure a
linear correlation between fluorescence intensity and drug
concentration in the tissue, for well known aggregation and
quenching phenomena can lead to a deviation from linearity.
In the present study intravital fluorescence microscopy was
compared to chemical extraction of microsurgically obtained
tissue samples from monitored areas. The agreement of
results within experimental errors demonstrates the validity
of the approach (Table IV).
The results of the present investigation demonstrate that
preferential localisation in tumours is not a feature common
to all porphyrinoids. Among the three pure model com-
pounds tested, only the most lipophilic dye, ATPPn, showed
a strong positive affinity for the amelanotic melanoma (A-
Mel-3). The tissue kinetics of this tumour selective por-
phycene (ATPPn) and Photofrin appear strikingly similar
(Figure 4a and d). Both sensitisers show the increase in
tumour-selectivity (Figure 5a and b) during the uptake phase
into tissues. For ATPPn the uptake nature of the tumour
localisation is additionally demonstrated by the similarity of
time constants for the rise in tumour-specificity (260 +
150 min) and the distribution from the serum (430 ± 30 min).
The prolonged uptake of Photofrin compared to ATPPn can
be rationalised in terms of the long persistence of a distinct
hydrophobic fraction of the porphyrin mixture in the serum
(Bellnier et al., 1989).
The observed accumulation of ATPPn and Photofrin dur-
ing their delivery from the bloodstream strongly suggests that
uptake and not retention-type tumour-localisation mechan-
isms lead to the tumour preferential localisation of por-
phyrines. If compromised lymphatic drainage (Gullino, 1975)
and/or prolonged retention of protogenic molecules in low
pH tissues (Brault et al., 1986; Barret et al., 1990) were the
underlying localisation mechanisms, an increase of the
tumour selectivity should appear during the elimination
phases of tissue kinetics. The decrease in tumour:skin tissue
ratio during the elimination of HEPn and ATPPn (Figure 5a)
points to the absence of a specific dye retention in the
tumour model used in this study.
From our results, a model can be proposed to explain the
localisation kinetics of Photofrin. Assuming that the Photo-
frin mixture contains a fraction of anti-tumour selective
molecules like HEPn besides an ATPPn-like localising frac-
tion its lower selectivity can be explained. This assumption
seems reasonable because the dihydroxyethylporphyrine
hematoporphyrine, is known to be present in Photofrin
(Dougherty et al., 1987). Since the time constant for the
process leading to the anti-tumour selectivity of HEPn is
similar to the time constant of the positive process of ATPPn
(Table III), the two Photofrin fractions corresponding to
these porphycenes might localise coincidently in opposite
'directions'. Thus, the weak time dependence in the tumour-
selectivity of Photofrin (Figure Sb) is understandable.
Photofrin is known to be lipophilic (Dougherty et al.,
1983; Kessel & Chou, 1983; Dougherty, 1987) and ATPPn is
the most lipophilic sensitiser among the porphycenes tested.
ATPPn remains within lipoprotein serum carrier particles for
hydrophobic molecules or residual liposomes as indicated by
its low concentration in erythrocytes (Table II). This finding
is in accordance with earlier studies with a similar por-
phycene (Guardiano et al., 1989). The porphyrins in photof-
rin will probably form aggregates in watery solutions or,
upon injection, become associated with serum proteins
(Cohen & Margalit, 1990). The negligible uptake of ATPPn230 M. LEUNIG et al.
150
T p<0.OOl
100
a)
200
qa)
c
a)
U)
U)
100
U-
20
a) cr
.-
a) U c 10
a)
0
cn
p
50
a)
X 40
a)
c 30
a)
U)
O 20
0
10
0
20
p > 0.25
a
I I . l ii . .l . l
40 60 80
b
C
24
Time after injection (h)
80
Figure 4 Tissue fluorescence-kinetics in the melanoma and skin tissue. a, ATPPn; b, HEPn; c, CBPn; d, Pf. Closed circles indicate
tumour, open circles tumor-free subcutaneous tissue. Fluorescence intensities of selected areas in tumour and tumour-free tissue are
given relative to solid fluorescence reference signals as mean ± s.e.m. Tumour fluorescence was significantly higher compared to the
tumour-free subcutaneous tissue for ATPPn and Pf (P<0.001), not significantly different for CBPn, and significantly lower for
HEPn (P<.OO1). Note the x-axis of the CBPn plot being 1/3 of other plots.TUMOUR LOCALISATION OF PORPHYRINOIDS 231
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Figure 5 Tumour to skin tissue ratios. a, ATPPn and HEPn; b, CBPn and Photofrin. Tumour to tumour-free tissue ratios in
fluorescence intensities of monitored areas as determined by intravital microscopy. Values are mean of the ratio of individual
animals ± s.e.m.
Table III Time to reach half maximum (t1) and maximum (tmax)
tumour selectivity ratio
Sensitizer ti (min)* tm. (h)'
Pf (a) I
ATPPn 260 150 24
HEPn 170 ± 30(b) 0.01
CBPn (c) 6
Values are mean ± s.d. (a) Not unambiguously evaluable, (b)
process leading to skin tissue selective localisation, and (c) no time
dependence. *Determined by a monoexponential fit process to data
of Figure 5. tDirectly obtained from acquired data.
in skin tissue furthermore demonstrates that there is no fast
membrane bound mechanism leading to the uptake of this
sensitiser. The tissue uptake of ATPPn and Photofrin might,
therefore, be governed by their macromolecular carrier par-
ticles rather than by the molecules themselves. Interstitial
concentrations of IgG in tumours after a bolus injection as
reported by Jain & Baxter (1988) showed a similar time
course of accumulation compared to ATPPn and Photofrin
further supporting a delivery of these photosensitisers via
serum macromolecules.
The macromolecules can accumulate in tumours either by
endocytotic processes or by extravasating from the blood
through holes in the endothelial lining. Both an enhanced
number of LDL receptors on tumour cells (Gal et al., 1981;
Norata et al., 1985; Maziere et al., 1991) and high vascular
permeability of tumours for macromolecules (Jain, 1987) are
known. If the endocytotic activity of the tumour cells was the
main accumulation mechanism, the interstitial fluid of
tumours should be impoverished in sensitiser compared to
the surrounding tissue and tumour cells should show bright
fluorescence. The microscopic pictures revealed, however,
strongly fluorescent tumour edge edema in (Figure 6b) as
expected for vascular permeability as major reason for the
tumour localisation.
The permeability hypothesis might also explain the selec-
tivity found for a wide range of different photosensitisers
(Gomer, 1991), many of which were shown to have an
affinity to macromolecular carrier particles in the blood-
stream, like lipoproteins or albumin (Cohen et al., 1990). In
accordance with this 'vascular' localisation process, no
difference in sensitiser uptake had been found between malig-
nant and non-malignant cell lines in vitro (Moan et al.,
1981).232 M. LEUNIG et al.
Figure 6 Photomicrographs of the amelanotic melanoma. a, Trans-illumination, photomicrograph of an A-Mel-3 tumour
(diameter: 4 mm) localised at the left lower edge of the chamber preparation, 6 days after implantation. b, Epi-illumination 24 h
subsequent to i.v. injection of 1.4pmol kg-' b.w. ATPPn as recorded by intravital microscopy. Note the strong fluorescence within
the tumour surrounding edema. c, Epi-illumination of a tumour chamber 24 h after i.v. injection of 1.4timol kg-' b.w. HEPn. Note
the non fluorescent tumour and tumour surrounding edema. The two fluorescent squares at the top of the chamber represent the
reference signals. (The bars represent 2 mm).
Table IV (a) Tumour selectivity ratio at 6 h (r6) and 72 h (r72), and
maximum tumour selectivity ratio (rmax) as evaluated by fluorescence
microscopy
Sensitiser r6 (h) r72 (h) rmax)
Pf 1.6±0.2 1.7±0.4 1.7±0.3
ATPPn 2.3 ± 0.7 2.7 ± 1.3 3.2 ± 1.1
HEPn 0.6±0.2 0.3±0.1 1.3±0.2
CBPn 1.1±0.3 - 1.1±0.3
Values are mean ± s.d.
(b) Tumour selectivity ratio at 6 h (r6) and 72 h (r72) as evaluated by
chemical extraction
Sensitiser r6 (h) r7, (h)
Pf _ _
ATPPn 1.8 ± 0.4* 2.0 ± 0.6
HEPn 0.64 ± 0.1* 0.4 ± 0.2
CBPn 1.1 ± 0.2*
Values are mean ± s.d. except for those marked *, these are
mean ± error of two extractions.
Further evidence for the 'selective macromolecule filtration
assumption of macromolecules comes from the localisation
of the non-tumour selective porphycenes HEPn and CBPn.
Unlike macromolecular bound molecules (Nugent & Jain,
1984), HEPn and CBPn are fast distributed from the blood
(Table I) as seen for small molecules (Gerlowski & Jain,
1983; Gibaldi & Perrier, 1982) and penetrate erythrocytes
effectively (Table II). Small standard deviations of the tissue
distributions (Figure 4b and c) support distribution processes
driven by physical gradients for small molecules.
The almost instantaneous tissue uptake of CBPn, which
reached its maximum 30s after the end of dye injection
favours free diffusion as possible transport mechanism. The
distribution of the less polar hydroxyporphycene HEPn prob-
ably proceeds via fast membrane uptake as it has been
observed for the hydroxysteroid cholesterol (Barclay et al.,
1990). HEPn reaches its maximum tissue concentrations
relatively slowly, probably via diffusion along hydrophobic
structures. The equilibrium distribution pattern seems to be
governed by the amount of hydrophobic sites within a tissue.
Highly fluorescent fat cells found in the subcutaneous host
tissue at high magnification and the high water content of theTUMOUR LOCALISATION OF PORPHYRINOIDS 233
amelanotic melanoma* support this explanation. Hence, the
pharmacokinetics of HEPn do not seem to favour earlier
assumptions of a general accumulation of lipophilic mole-
cules by sensitiser retaining tissues (Freitas, 1990).
In conclusion, our study demonstrates that intravital mic-
roscopy is a valuable tool for the study of porphyrinoid
pharmacokinetics. Investigating synthetic porphyrinoids of
variable lipophilicity, it was shown that polar functional
groups accelerate the pharmacokinetics of photosensitisers.
The most lipophilic porphycene studied accumulated in
tumours twice as much as Photofrin. Local tumour selectivity
of sensitisers was found to originate in uptake and not
elimination processes in the body compartment monitored.
Increased permeability of the tumour vasculature to carrier
macromolecules probably plays a governing role in the
localisation process. Extension of these experiments to other
physiological compartments, tumour models and photosen-
sitisers will be needed to support these conclusions.
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SIT, Silicon intensified target.
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